Claims
- 1. A method of treating inflammation in a subject comprising administering to the subject an effective amount of a peptide having the general formula (I),
- 2. The method of claim 1, wherein the peptide, or salt or amide thereof, comprises a peptide derived from the Aalpha-chain of fibrin.
- 3. The method of claim 1, wherein the peptide, or salt or amide thereof, comprises a peptide derived from the Bbeta-chain of fibrin.
- 4. A method of treating inflammation in a subject comprising administering to the subject an effective amount of a peptide having the general formula (II),
- 5. The method of claim 4, wherein Z5 is a peptide comprising an amino acid sequence set forth in SEQ ID NO:291,
- 6. The method of claim 5, wherein Z1 is histidine, Z3 is proline, and Z4 is leucine.
- 7. The method of claim 6, wherein the peptide, or salt or amide thereof comprises the amino acid sequence (SEQ ID NO: 294):
- 8. The method of claim 4, wherein Z5 is a peptide comprising an amino acid sequence set forth in SEQ ID NO:292,
- 9. The method of claim 8, wherein Z1 is proline, Z3 is valine, and Z4 is valine.
- 10. The method of claim 9, wherein the peptide, salt or amide thereof comprises the amino acid sequence (SEQ ID NO: 293):
- 11. A method of preventing inflammation in a subject comprising administering to the subject an effective amount of a peptide having the general formula (I),
- 12. The method of claim 11, wherein the peptide, or salt or amide thereof, comprises a peptide derived from the Aalpha-chain of fibrin.
- 13. The method of claim 11, wherein the peptide, or salt or amide thereof, comprises a peptide derived from the Bbeta-chain of fibrin.
- 14. A method of preventing inflammation in a subject comprising administering to the subject an effective amount of a peptide having the general formula (II),
- 15. The method of claim 14, wherein Z5 is a peptide comprising an amino acid sequence set forth in SEQ ID NO:291,
- 16. The method of claim 15, wherein Z1 is histidine, Z3 is proline, and Z4 is leucine.
- 17. The method of claim 16, wherein the peptide, or salt or amide thereof comprises the amino acid sequence (SEQ ID NO: 294):
- 18. The method of claim 14, wherein Z5 is a peptide comprising an amino acid sequence set forth in SEQ ID NO:292,
- 19. The method of claim 18, wherein Z1 is proline, Z3 is valine, and Z4 is valine.
- 20. The method of claim 19, wherein the peptide, salt or amide thereof comprises the amino acid sequence (SEQ ID NO: 293):
- 21. The method of claim 1, 4, 11 or 14, wherein the inflammation is due to a condition selected from the group consisting of an infection, an autoimmune condition, a rheumatic disorder, or a disorder of the immune system.
- 22. A method of treating rejection of a transplanted tissue in a subject comprising administering to the subject an effective amount of a peptide having the general formula (I),
- 23. The method of claim 22, wherein the peptide, or a salt or amide thereof, comprises a peptide derived from a source selected from the group consisting of the Aalpha-chain of fibrin and the Bbeta chain of fibrin.
- 24. A method of treating rejection of a transplanted tissue in a subject comprising administering to the subject an effective amount of a peptide having the general formula (II),
- 25. The method of claim 24, wherein Z5 is a peptide comprising an amino acid sequence set forth in SEQ ID NO:291,
- 26. The method of claim 4, wherein Z5 is a peptide comprising an amino acid sequence set forth in SEQ ID NO:292,
- 27. A method of preventing rejection of a transplanted tissue in a subject comprising administering to the subject an effective amount of a peptide having the general formula (I),
- 28. The method of claim 27, wherein the peptide, or a salt or amide thereof, comprises a peptide derived from a source selected from the group consisting of the Aalpha-chain of fibrin and the Bbeta chain of fibrin.
- 29. A method of preventing rejection of a transplanted tissue in a subject comprising administering to the subject an effective amount of a peptide having the general formula (II),
- 30. The method of claim 29, wherein Z5 is a peptide comprising an amino acid sequence set forth in SEQ ID NO:291,
- 31. The method of claim 29, wherein Z5 is a peptide comprising an amino acid sequence set forth in SEQ ID NO:292,
- 32. A method of treating arterial sclerosis in a subject comprising administering to the subject an effective amount of a peptide having the general formula (I),
- 33. The method of claim 32, wherein the peptide, or a salt or amide thereof, comprises a peptide derived from a source selected from the group consisting of the Aalpha-chain of fibrin and the Bbeta chain of fibrin.
- 34. A method of treating arterial sclerosis in a subject comprising administering to the subject an effective amount of a peptide having the general formula (II),
- 35. The method of claim 34, wherein Z5 is a peptide comprising an amino acid sequence set forth in SEQ ID NO:291,
- 36. The method of claim 34, wherein Z5 is a peptide comprising an amino acid sequence set forth in SEQ ID NO:292,
- 37. A method of preventing arterial sclerosis in a subject comprising administering to the subject an effective amount of a peptide having the general formula (I),
- 38. The method of claim 37, wherein the peptide, or a salt or amide thereof, comprises a peptide derived from a source selected from the group consisting of the Aalpha-chain of fibrin and the Bbeta chain of fibrin.
- 39. A method of preventing arterial sclerosis in a subject comprising administering to the subject an effective amount of a peptide having the general formula (II),
- 40. The method of claim 39, wherein Z5 is a peptide comprising an amino acid sequence set forth in SEQ ID NO:291,
- 41. The method of claim 39, wherein Z5 is a peptide comprising an amino acid sequence set forth in SEQ ID NO:292,
- 42. The method of claim 32, 34, 37 or 39 wherein arterial sclerosis is treated or prevented in a transplanted tissue in a subject.
- 43. A method of treating reperfusion injury in a subject comprising administering to the subject an effective amount of a peptide having the general formula (I),
- 44. The method of claim 43, wherein the peptide, or a salt or amide thereof, comprises a peptide derived from a source selected from the group consisting of the Aalpha-chain of fibrin and the Bbeta chain of fibrin.
- 45. A method of treating reperfusion injury in a subject comprising administering to the subject an effective amount of a peptide having the general formula (II),
- 46. The method of claim 45, wherein Z5 is a peptide comprising an amino acid sequence set forth in SEQ ID NO:291,
- 47. The method of claim 45, wherein Z5 is a peptide comprising an amino acid sequence set forth in SEQ ID NO:292,
- 48. A method of preventing reperfusion injury in a subject comprising administering to the subject an effective amount of a peptide having the general formula (I),
- 49. The method of claim 48, wherein the peptide, or a salt or amide thereof, comprises a peptide derived from a source selected from the group consisting of the Aalpha-chain of fibrin and the Bbeta chain of fibrin.
- 50. A method of preventing reperfusion injury in a subject comprising administering to the subject an effective amount of a peptide having the general formula (II),
- 51. The method of claim 50, wherein Z5 is a peptide comprising an amino acid sequence set forth in SEQ ID NO:291,
- 52. The method of claim 50, wherein Z5 is a peptide comprising an amino acid sequence set forth in SEQ ID NO:292,
- 53. A method of treating thrombotic disease in a subject comprising administering to the subject an effective amount of a peptide having the general formula (I),
- 54. The method of claim 54, wherein the peptide, or a salt or amide thereof, comprises a peptide derived from a source selected from the group consisting of the Aalpha-chain of fibrin and the Bbeta chain of fibrin.
- 55. A method of treating thrombotic disease in a subject comprising administering to the subject an effective amount of a peptide having the general formula (II),
- 56. The method of claim 55, wherein Z5 is a peptide comprising an amino acid sequence set forth in SEQ ID NO:291,
- 57. The method of claim 55, wherein Z5 is a peptide comprising an amino acid sequence set forth in SEQ ID NO:292,
- 58. A method of preventing thrombotic disease in a subject comprising administering to the subject an effective amount of a peptide having the general formula (I),
- 59. The method of claim 58, wherein the peptide, or a salt or amide thereof, comprises a peptide derived from a source selected from the group consisting of the Aalpha-chain of fibrin and the Bbeta chain of fibrin.
- 60. A method of preventing thrombotic disease in a subject comprising administering to the subject an effective amount of a peptide having the general formula (II),
- 61. The method of claim 60, wherein Z5 is a peptide comprising an amino acid sequence set forth in SEQ ID NO:291,
- 62. The method of claim 60, wherein Z5 is a peptide comprising an amino acid sequence set forth in SEQ ID NO:292,
- 63. A method of preventing fibrin fragments from adhering to a vascular wall of a subject comprising administering to the subject an effective amount of a peptide having the general formula (I),
- 64. The method of claim 63, wherein the peptide, or a salt or amide thereof, comprises a peptide derived from the Bbeta chain of fibrin.
- 65. A method of preventing fibrin fragments from adhering to a vascular wall of a subject comprising administering to the subject an effective amount of a peptide having the general formula (II),
- 66. The method of claim 39, wherein Z5 is a peptide comprising an amino acid sequence set forth in SEQ ID NO:291,
- 67. A method of transporting a drug substance to a cell in a subject comprising administering to the subject an effective amount of a peptide having the general formula (I),
- 68. A method of transporting a drug substance to a cell in a subject comprising administering to the subject an effective amount of a peptide having the general formula (II),
- 69. The method of claim 39, wherein Z5 is a peptide comprising an amino acid sequence set forth in SEQ ID NO:291,
- 70. A method of inhibiting adhesion of cells in the bloodstream to endothelial cells of the vascular wall of a subject comprising administering to the subject an effective amount of a peptide having the general formula (I),
- 71. The method of claim 70, wherein the peptide, or a salt or amide thereof, comprises a peptide derived from a source selected from the group consisting of the Aalpha-chain of fibrin and the Bbeta chain of fibrin.
- 72. A method of inhibiting adhesion of cells in the bloodstream to endothelial cells of the vascular wall of a subject in a subject comprising administering to the subject an effective amount of a peptide having the general formula (II),
- 73. The method of claim 72, wherein Z5 is a peptide comprising an amino acid sequence set forth in SEQ ID NO:291,
- 74. The method of claim 72, wherein Z5 is a peptide comprising an amino acid sequence set forth in SEQ ID NO:292,
Priority Claims (1)
| Number |
Date |
Country |
Kind |
| AT A 2063/2000 |
Dec 2000 |
AT |
|
CROSS REFERENCE TO RELATED APPLICATION(S)
[0001] The present application is a continuation of International Patent Application No. PCT/AT01/00387, filed Dec. 7, 2001, published in German on Jun. 20, 2002 as International Patent Publication No. WO02/248180, which claims priority to Austrian Application No. AT A 2063/2000, filed Dec. 12, 2000, all of which are incorporated in their entireties herein.
Continuations (1)
|
Number |
Date |
Country |
| Parent |
PCT/AT01/00387 |
Dec 2001 |
US |
| Child |
10459030 |
Jun 2003 |
US |
Patent Application
20040192596
